Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.37−0.39 (-5.03%)
Close on Nov 16, 2026Market cap $395.25MP/E –Yield –
Avalo Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Avalo Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -132642.4%. For fiscal 2025 it was -132642.4%, against -7965.8% the year before. The highest annual figure on record is 42.7% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -132642.4% | −124676.6 |
| FY2024 | Dec 31, 2024 | -7965.8% | −6326.3 |
| FY2023 | Dec 31, 2023 | -1639.5% | −1408.7 |
| FY2022 | Dec 31, 2022 | -230.8% | +1332.3 |
| FY2021 | Dec 31, 2021 | -1563.1% | −615.2 |
| FY2020 | Dec 31, 2020 | -947.9% | −709.8 |
| FY2019 | Dec 31, 2019 | -238.1% | +331.8 |
| FY2018 | Dec 31, 2018 | -569.9% | −612.5 |
| FY2017 | Dec 31, 2017 | 42.7% | +1471.3 |
| FY2016 | Dec 31, 2016 | -1428.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -23254.2% | −21039.0 |
| Q4 FY2024 | Dec 31, 2024 | -18405.7% | −17131.5 |
| Q3 FY2024 | Sep 30, 2024 | 9251.8% | +11347.6 |
| Q4 FY2023 | Dec 31, 2023 | -1430.5% | −335.4 |
| Q3 FY2023 | Sep 30, 2023 | -2215.3% | −2236.6 |
| Q2 FY2023 | Jun 30, 2023 | -1274.2% | −17.0 |
| Q1 FY2023 | Mar 31, 2023 | -2095.8% | −215.9 |
| Q4 FY2022 | Dec 31, 2022 | -1095.1% | +7670.2 |
| Q3 FY2022 | Sep 30, 2022 | 21.4% | +1309.9 |
| Q2 FY2022 | Jun 30, 2022 | -1257.2% | −747.4 |
| Q1 FY2022 | Mar 31, 2022 | -1879.9% | +4606.4 |
| Q4 FY2021 | Dec 31, 2021 | -8765.3% | −7720.3 |
| Q3 FY2021 | Sep 30, 2021 | -1288.5% | −77.1 |
| Q2 FY2021 | Jun 30, 2021 | -509.8% | +482.8 |
| Q1 FY2021 | Mar 31, 2021 | -6486.3% | −5719.5 |
| Q4 FY2020 | Dec 31, 2020 | -1045.0% | −1324.1 |
| Q3 FY2020 | Sep 30, 2020 | -1211.4% | −1029.0 |
| Q2 FY2020 | Jun 30, 2020 | -992.6% | −545.5 |
| Q1 FY2020 | Mar 31, 2020 | -766.8% | −477.5 |
| Q4 FY2019 | Dec 31, 2019 | 279.1% | +390.6 |
| Q3 FY2019 | Sep 30, 2019 | -182.5% | +421.3 |
| Q2 FY2019 | Jun 30, 2019 | -447.1% | −321.5 |
| Q1 FY2019 | Mar 31, 2019 | -289.3% | −202.7 |
| Q4 FY2018 | Dec 31, 2018 | -111.5% | +50.2 |
| Q3 FY2018 | Sep 30, 2018 | -603.8% | −678.6 |
| Q2 FY2018 | Jun 30, 2018 | -125.5% | +1014.2 |
| Q1 FY2018 | Mar 31, 2018 | -86.6% | +423.7 |
| Q4 FY2017 | Dec 31, 2017 | -161.7% | +743.8 |
| Q3 FY2017 | Sep 30, 2017 | 74.8% | +1993.6 |
| Q2 FY2017 | Jun 30, 2017 | -1139.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -510.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -905.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -1918.8% | – |
See a number that looks wrong?